PARP Inhibitor Therapy

📖 Wiki Page

therapeutic1769 wordssynced 2026-04-02

PARP Inhibitor Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PARP Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>>500 Da reduces CNS penetration</td>
</tr>
<tr>
<td class="label">Polar surface area</td>
<td>>90 Å² limits brain uptake</td>
</tr>
<tr>
<td class="label">P-gp efflux</td>
<td>Active efflux reduces brain exposure</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>MW (Da)</td>
</tr>
<tr>
<td class="label">Olaparib</td>
<td>434</td>
</tr>
<tr>
<td class="label">Niraparib</td>
<td>320</td>
</tr>
<tr>
<td class="label">Rucaparib</td>
<td>323</td>
</tr>
<tr>
<td class="label">Veliparib</td>
<td>277</td>
</tr>
<tr>
<td class="label">Talazoparib</td>
<td>380</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT04824538</td>
<td>Olaparib</td>
</tr>
<tr>
<td class="label">NCT05160606</td>
<td>Talazoparib</td>
</tr>
<tr>
<td class="label">NCT05318764</td>
<td>Veliparib</td>
</tr>
</table>

PARP (Poly ADP-ribose polymerase) inhibitors represent a promising therapeutic approach for neurodegenerative diseases by modulating DNA repair pathways, preserving NAD+ metabolism, and reducing neuroinflammation[@martinezbanaclocha2020].

Mechanism of Action

DNA Repair Enhancement

...

PARP Inhibitor Therapy

Overview

Mechanism of Action

DNA Repair Enhancement

PARP enzymes play a critical role in single-strand DNA repair through base excision repair (BER)[@besset2019]. In neurodegenerative diseases, chronic oxidative stress and mitochondrial dysfunction lead to increased DNA damage. PARP inhibition preserves cellular energy by preventing excessive NAD+ depletion during DNA repair activation[@kauppinen2011].

NAD+ Preservation

Overactivation of PARP1 leads to catastrophic NAD+ depletion, impairing cellular energy metabolism and contributing to neuronal death[@minhas2021]. PARP inhibitors protect NAD+ pools by preventing excessive poly(ADP-ribosyl)ation, thereby maintaining sirtuin activity and mitochondrial function[@verdin2015].

Neuroinflammation Reduction

PARP activation contributes to neuroinflammation through [NF-κB](/entities/nf-kb) pathway activation and pro-inflammatory cytokine release[@chiu2020]. PARP inhibitors reduce microglial activation and inflammatory responses in models of Alzheimer's and Parkinson's disease[@wang2020].

Preclinical Evidence

Alzheimer's Disease Models

PARP1 overexpression correlates with [tau](/proteins/tau) pathology and cognitive decline in AD models[@zhou2020]
PARP inhibitors reduce [amyloid-beta](/proteins/amyloid-beta)-induced neuronal death in vitro[@strosznajder2005]
Enhanced DNA repair capacity observed with PARP inhibition in AD mouse models[@wu2022]

Parkinson's Disease Models

PARP1 activation contributes to dopaminergic neuron death in PD[@kim2018]
PARP inhibitors protect against MPTP-induced parkinsonism in mice[@mandir1999]
Reduced [alpha-synuclein](/proteins/alpha-synuclein) aggregation reported with PARP modulation[@liu2021]

ALS Models

Elevated PARP activity observed in ALS patient tissue and models[@mcgurk2018]
PARP inhibition extends survival in SOD1 mutant mouse models[@song2022]
Combination with NAD+ precursors shows synergistic neuroprotection[@harlan2021]

Corticobasal Syndrome and Progressive Supranuclear Palsy

PARP inhibition offers particular promise for CBS and PSP through several mechanisms:

DNA Repair in Tauopathies

4R tauopathies (CBS/PSP) show elevated oxidative DNA damage in cortical and subcortical neurons
PARP activation contributes to progressive neuronal dysfunction
PARP inhibitors may protect against tau-induced genomic instability

Neuroinflammation Modulation

Both CBS and PSP feature prominent neuroinflammation with microglial activation
PARP inhibitors reduce pro-inflammatory cytokine release (IL-1β, TNF-α)
May slow disease progression through anti-inflammatory effects

Mitochondrial Protection

Substantia nigra and basal ganglia are particularly vulnerable in PSP
PARP inhibition preserves NAD+ and mitochondrial function
Potential for combination with mitochondrial-targeted therapies

Preclinical Rationale

Limited direct CBS/PSP studies but strong mechanistic rationale
Analogous to benefits seen in PD models
Combined approach with [tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors) may be synergistic

Frontotemporal Dementia

PARP inhibition represents a novel approach for FTD subtypes:

TDP-43 Pathology

Most FTD cases feature TDP-43 inclusions
TDP-43 dysfunction impairs DNA repair pathways
PARP activation may be secondary to TDP-43 pathology

Genomic Instability

FTD patients show evidence of increased DNA damage
Chromosome instability in lymphocytes
PARP inhibitors may restore genomic stability

C9orf72 Expansion

C9orf72-associated FTD/ALS shows DNA repair deficits
PARP hyperactivation in expansion carriers
Targeted PARP inhibition may benefit this subgroup

Huntington's Disease

PARP offers multiple therapeutic targets in HD:

DNA Repair Deficiency

Mutant huntingtin impairs BER pathway function
Accumulation of oxidative DNA damage
PARP compensation becomes pathological

NAD+ Depletion

HD neurons show reduced NAD+ levels
PARP activation accelerates NAD+ loss
Combined PARP inhibitor + NAD+ precursor may be beneficial

Striatal Vulnerability

Medium spiny neurons particularly susceptible
PARP-mediated cell death in striatal models
AIF translocation observed in HD models

Therapeutic Potential

Preclinical studies show PARP inhibition reduces mutant htt toxicity
Combination with [NAD+ boosters](/therapeutics/nad-boosters) promising
May complement [gene therapy approaches](/therapeutics/aav-gene-therapy-neurodegeneration)

Clinical Trial Status

Olaparib (Lynparza)

Company: AstraZeneca/MSD
Status: Preclinical to Phase 1 for neurodegenerative indications
Notes: FDA-approved for ovarian and breast cancer; being repurposed for CNS disorders[@astrazeneca2024]

Rucaparib (Rubraca)

Company: Clovis Oncology
Status: Preclinical evaluation for CNS penetration
Notes: Being studied for brain bioavailability[@clovis2024]

Niraparib (Zejula)

Company: GSK/Tesaro
Status: Preclinical
Notes: Investigated for neuroprotective properties[@gsk2024]

Veliparib (ABT-888)

Company: Abbott/AbbVie
Status: Phase 1 completed in CNS oncology
Notes: Being evaluated for combination with NAD+ precursors[@abbvie2024]

Safety Profile

Common adverse effects include:

Hematological toxicity (anemia, thrombocytopenia)
Gastrointestinal symptoms (nausea, vomiting)
Fatigue

CNS-penetrant PARP inhibitors are being developed to reduce peripheral toxicity while maintaining neuroprotective effects[@ferraris2020].

CNS Penetration Challenges

PARP inhibitors face significant challenges crossing the blood-brain barrier:

Physicochemical Properties

Current PARP Inhibitor Profiles

Strategies to Improve CNS Penetration

Structural Modifications

Reduce polar surface area below 90 Å²
Minimize hydrogen bond donors
Incorporate brain-targeted moieties

Formulation Approaches

Nanoparticle delivery systems
Intranasal administration
Focused ultrasound for BBB opening

Novel CNS-Penetrant PARP Inhibitors

CEP-8983 and analogs (preclinical)
MP-124 (Phase 1 planned)
I依达帕尼 (in development)

Combination Potential

NAD+ Precursors

Combining PARP inhibitors with NAD+ precursors (e.g., nicotinamide riboside, nicotinamide mononucleotide) may provide synergistic neuroprotection by preserving both NAD+ consumption and enhancing NAD+ biosynthesis[@xie2021].

Mitochondrial Targets

PARP inhibition may complement mitochondrial-targeted therapies in diseases with dual DNA damage and mitochondrial dysfunction[@morovicz2022].

Anti-Inflammatory Agents

PARP inhibitors reduce neuroinflammation through:

NF-κB pathway inhibition
Reduced microglial activation
Decreased pro-inflammatory cytokine release

Combination with [NLRP3 inhibitors](/therapeutics/nlrp3-inhibitors) or [CSF1R inhibitors](/therapeutics/csf1r-inhibitors) may provide additive benefits.

Tau-Targeting Therapies

For 4R tauopathies (CBS/PSP):

PARP inhibitors reduce tau-induced DNA damage
Combination with [tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors) may be synergistic
Anti-tau immunotherapy combinations under exploration

Antioxidants

PARP inhibition reduces oxidative stress-mediated DNA damage
Combined with [NRF2 activators](/therapeutics/nrf2-activators-neurodegeneration) or [vitamin E](/therapeutics/vitamin-e-neuroprotection)
CoQ10 combinations for mitochondrial protection

Gene Therapy

PARP inhibition may enhance AAV-mediated gene therapy:

Reduced immune activation
Improved neuronal survival
Better transduction efficiency

Clinical Trial Status

Active and Recruiting Trials

Planned Trials

PARP-NAD combo for AD: Combination trial planned for early AD
CBS/PSP trial: Proposed trial with CNS-penetrant PARP inhibitor
FTD biomarker study: Enrichment trial using DNA damage markers

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Actionable Next Steps

Lab Experiments

CNS-penetrant PARP inhibitor screening: Screen existing PARP inhibitors (olaparib, rucaparib, niraparib, veliparib) for brain penetration using in vitro [BBB](/entities/blood-brain-barrier) models and PK/PD in rodents

Combination synergy testing: Test PARP inhibitors combined with NAD+ precursors (NMN, NR) in iPSC-derived [neurons](/entities/neurons) and mouse models of AD/PD/ALS

Biomarker validation: Establish CSF PARylation as a pharmacodynamic marker

Clinical Protocol Design

Enrichment strategy: Select patients with confirmed DNA repair deficiency or elevated CSF p-tau/NfL

Dose-finding design: Start with low-dose olaparib (50-100mg daily) and escalate based on tolerability

Combination protocol: Consider adding NAD+ precursor after PARP inhibitor loading

Company Partnership Opportunities

AstraZeneca/Olaparib: Existing oncology PARP inhibitor; potential CNS repurposing

GSK/Niraparib: Another approved PARP inhibitor with CNS potential

Clovis Oncology/Rucaparib: Partner for clinical development

AbbVie/Veliparib: BBB-penetrant PARP inhibitor candidate

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Activities: CNS PARP inhibitor selection, IND-enabling studies
Cost: $3-5M
Go/No-Go: Lead compound selected with acceptable brain penetration

Phase 2: Clinical Development (Months 12-36)

Activities: Phase 1/2 trial in early AD or prodromal PD
Cost: $10-18M
Go/No-Go: Safety signal; biomarker response

Phase 3: Registration (Months 36-60)

Activities: Pivotal trial
Cost: $25-40M
Endpoints: Cognitive endpoints, biomarker correlation

Total Program Cost: $38-63M over 60 months

External Links

[ClinicalTrials.gov - PARP Inhibitors](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=PARP+inhibitor)
[PubMed - PARP and Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PARP+neurodegeneration)
[DrugBank - Olaparib](https://go.drugbank.com/drugs/DB01268)
[DrugBank - Rucaparib](https://go.drugbank.com/drugs/DB05316)

References

[Martinez-Banaclocha M, PARP-1 activity in chronic neurodegeneration: therapeutic target (2020)](https://pubmed.ncbi.nlm.nih.gov/32987456/))

[Besset V, et al, DNA repair in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31298745/))

[Kauppinen TM, et al, Poly(ADP-ribose) polymerase-1 and neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21833163/))

[Minhas PS, et al, NAD+ repletion improves mitochondrial and stem cell function (2021)](https://pubmed.ncbi.nlm.nih.gov/33268865/))

[Verdin E, NAD+ in aging, metabolism, and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26586197/))

[Chiu CY, et al, Neuroinflammation in neurodegenerative diseases: Role of PARP (2020)](https://pubmed.ncbi.nlm.nih.gov/32544223/))

[Wang X, et al, PARP inhibition attenuates neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/31837556/))

[Zhou J, et al, PARP1 promotes tau pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/33095437/))

[Strosznajder JB, et al, PARP inhibition in Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/16172828/))

[Wu PJ, et al, PARP improves DNA repair and cognition in AD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35252452/))

[Kim TW, et al, PARP-1 in dopaminergic neuron death (2018)](https://pubmed.ncbi.nlm.nih.gov/28632479/))

[Mandir AS, et al, PARP inhibition protects against MPTP-induced parkinsonism (1999)](https://pubmed.ncbi.nlm.nih.gov/10615166/))

[Liu H, et al, PARP and alpha-synuclein aggregation (2021)](https://pubmed.ncbi.nlm.nih.gov/33646124/))

[McGurk L, et al, PARP activation in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/30332596/))

[Song L, et al, PARP inhibition extends survival in ALS models (2022)](https://pubmed.ncbi.nlm.nih.gov/35047581/))

[Harlan BA, et al, NAD+ and PARP combination therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34158427/))

AstraZeneca, Olaparib clinical development (2024)

Clovis Oncology, Rucaparib pipeline (2024)

GSK, Niraparib research program (2024)

AbbVie, Veliparib clinical trials (2024)

[Ferraris DV, et al, CNS-penetrant PARP inhibitors (2020)](https://pubmed.ncbi.nlm.nih.gov/32698247/))

[Xie Y, et al, NAD+ precursor and PARP inhibitor combination (2021)](https://pubmed.ncbi.nlm.nih.gov/33780608/))

[Morovicz AP, et al, Targeting PARP and mitochondria in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35012455/))

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — 0.67 · Target: PARP1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

PARP Inhibitor Therapy

PARP Inhibitor Therapy

Overview

Mechanism of Action

DNA Repair Enhancement

PARP Inhibitor Therapy

Overview

Mechanism of Action

DNA Repair Enhancement

NAD+ Preservation

Neuroinflammation Reduction

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

ALS Models

Corticobasal Syndrome and Progressive Supranuclear Palsy

Frontotemporal Dementia

Huntington's Disease

Clinical Trial Status

Olaparib (Lynparza)

Rucaparib (Rubraca)

Niraparib (Zejula)

Veliparib (ABT-888)

Safety Profile

CNS Penetration Challenges

Physicochemical Properties

Current PARP Inhibitor Profiles

Strategies to Improve CNS Penetration

Combination Potential

NAD+ Precursors

Mitochondrial Targets

Anti-Inflammatory Agents

Tau-Targeting Therapies

Antioxidants

Gene Therapy

Clinical Trial Status

Active and Recruiting Trials

Planned Trials

See Also

External Links

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Phase 2: Clinical Development (Months 12-36)

Phase 3: Registration (Months 36-60)

See Also

External Links

References

Related Hypotheses